Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MDxHealth (MDXH) Receivables - Other (2020 - 2023)

Historic Receivables - Other for MDxHealth (MDXH) over the last 4 years, with Q4 2023 value amounting to $36000.0.

  • MDxHealth's Receivables - Other fell 9961.53% to $36000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $36000.0, marking a year-over-year decrease of 9961.53%. This contributed to the annual value of $36000.0 for FY2023, which is 9961.53% down from last year.
  • Latest data reveals that MDxHealth reported Receivables - Other of $36000.0 as of Q4 2023, which was down 9961.53% from $9.4 million recorded in Q4 2022.
  • In the past 5 years, MDxHealth's Receivables - Other registered a high of $9.4 million during Q4 2022, and its lowest value of $36000.0 during Q4 2023.
  • Moreover, its 4-year median value for Receivables - Other was $4.2 million (2020), whereas its average is $4.4 million.
  • As far as peak fluctuations go, MDxHealth's Receivables - Other surged by 10421.21% in 2022, and later tumbled by 9961.53% in 2023.
  • Over the past 4 years, MDxHealth's Receivables - Other (Quarter) stood at $3.8 million in 2020, then grew by 21.51% to $4.6 million in 2021, then surged by 104.21% to $9.4 million in 2022, then tumbled by 99.62% to $36000.0 in 2023.
  • Its last three reported values are $36000.0 in Q4 2023, $9.4 million for Q4 2022, and $4.6 million during Q4 2021.